- Home
- SUPN vs NMM Comparison
SUPN vs NMM Comparison
Compare SUPN & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- NMM
- Stock Information
- Founded
- SUPN 2005
- NMM 2007
- Country
- SUPN United States
- NMM Greece
- Employees
- SUPN N/A
- NMM N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- NMM Marine Transportation
- Sector
- SUPN Health Care
- NMM Consumer Discretionary
- Exchange
- SUPN Nasdaq
- NMM Nasdaq
- Market Cap
- SUPN 1.8B
- NMM 1.1B
- IPO Year
- SUPN 2012
- NMM 2007
- Fundamental
- Price
- SUPN $33.18
- NMM $39.83
- Analyst Decision
- SUPN Hold
- NMM Strong Buy
- Analyst Count
- SUPN 2
- NMM 1
- Target Price
- SUPN $36.00
- NMM $80.00
- AVG Volume (30 Days)
- SUPN 790.6K
- NMM 93.3K
- Earning Date
- SUPN 08-05-2025
- NMM 08-19-2025
- Dividend Yield
- SUPN N/A
- NMM 0.52%
- EPS Growth
- SUPN N/A
- NMM N/A
- EPS
- SUPN 1.11
- NMM 11.16
- Revenue
- SUPN $667,997,000.00
- NMM $1,319,623,000.00
- Revenue This Year
- SUPN N/A
- NMM N/A
- Revenue Next Year
- SUPN $12.02
- NMM $7.93
- P/E Ratio
- SUPN $29.94
- NMM $3.59
- Revenue Growth
- SUPN 11.82
- NMM 0.28
- 52 Week Low
- SUPN $26.65
- NMM $28.37
- 52 Week High
- SUPN $40.28
- NMM $65.89
- Technical
- Relative Strength Index (RSI)
- SUPN 60.49
- NMM 57.44
- Support Level
- SUPN $31.35
- NMM $37.42
- Resistance Level
- SUPN $33.80
- NMM $39.52
- Average True Range (ATR)
- SUPN 0.92
- NMM 1.18
- MACD
- SUPN 0.16
- NMM 0.02
- Stochastic Oscillator
- SUPN 79.12
- NMM 85.15
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.